Gabapentin enacarbil

(Horizant®)

Horizant®

Drug updated on 11/16/2023

Dosage FormTablet (oral; 300 mg, 600 mg)
Drug ClassGamma-aminobutyric acid analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.
  • For the management of postherpetic neuralgia (PHN) in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Horizant (gabapentin enacarbil) Prescribing Information.2022Azurity Pharmaceuticals, LLC, Atlanta, GA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
The Management of Restless Legs Syndrome: An Updated Algorithm.2021Mayo Clinic Proceedings